fosmidomycin + clindamycin + artesunate

A combination therapy consisting of **fosmidomycin**, **clindamycin**, and **artesunate**. Each component acts as an antimalarial with distinct mechanisms: - **Fosmidomycin** inhibits 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) in the methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis, a pathway essential to Plasmodium species but absent in humans. - **Clindamycin** is a lincosamide antibiotic that interferes with the 50S ribosomal subunit, inhibiting protein synthesis and thus affecting the apicoplast function in Plasmodium. - **Artesunate** is a derivative of artemisinin, producing free radicals that are highly toxic to malaria parasites and causing rapid parasite clearance. This triple-combination targets multidrug-resistant *Plasmodium falciparum*, aiming to increase efficacy and prevent resistance. While fosmidomycin+clindamycin and fosmidomycin+artesunate combinations have been studied in clinical trials for malaria, formal clinical evaluation of all three drugs together (the exact "fosmidomycin + clindamycin + artesunate" combination) is limited or not yet widely published.